Est. 2001·3,000+ placements · six offices · four regions

Company signals · Biotech & Pharma

Biogen Inc.

1 signal in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; EMEA hiring signal is running rising (+5pts).

Biogen Inc.: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies.

Signals at Biogen Inc.

Biogen Inc. signals in the last 90 days

1 public signal observed since 22 August 2026, by type.

MitchelLake in this thematic

More signals across Biotech & Pharma

Product Launch · EMEA

AviadoBio →

AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.

Product Launch · EMEA

Boehringer Ingelheim →

Boehringer Ingelheim announced Phase III trial success for survodutide (BI 456906), a glucagon/GLP-1 receptor dual agonist, achieving 13.1% average weight loss in obesity and type 2 diabetes patients. Results published in NEJM and presented at EASD conference.

Product Launch · EMEA

Teva Pharmaceuticals →

Teva Pharmaceuticals reported successful topline results from a gluten challenge study showing that a single injection of an experimental antibody significantly reduced intestinal damage in celiac disease patients who consumed gluten daily.

Product Launch · EMEA

Biogen →

Biogen and Eisai gained FDA approval for LEQEMBI IQLIK, an at-home subcutaneous autoinjector for Alzheimer's treatment, plus Phase 2 data showing tau reduction with investigational therapy diranersen. Positions Biogen as leader in amyloid- and tau-targeting approaches.

Product Launch · EMEA

Bristol Myers Squibb →

Bristol Myers Squibb reported positive Phase III clinical trial results for mezigdomide (multiple myeloma) and early-stage CAR T-cell therapy arlocabtagene autoleucel with strong response rates and manageable safety profiles, presented at European Hematology Association Congress 2026.

Product Launch · EMEA

Amgen →

European Commission approved Amgen's IMDYLLTRA® for extensive-stage small cell lung cancer treatment, demonstrating 40% reduction in death risk versus chemotherapy in Phase 3 trial

Where Biogen Inc.'s market lands in our work

Weekly briefing

Track companies like Biogen Inc. — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record

MitchelLake is a global executive search and advisory firm covering AI, innovation and expansion leadership for companies navigating transformation and change across industries, from startups and scale-ups to private-equity-backed and enterprise organisations. 3,000+ C-suite, specialist and board placements since 2001.

Data period
2 Oct 2026 – 2 Oct 2026 · 1 signals for this company
Publisher
MitchelLake

Last updated